This Month in Business
Luxturna marketing rights, bionic vision systems, and preservative-free formulations
Ruth Steer |
- Novartis and Spark Therapeutics have entered a licensing agreement for Luxturna (voretigene neparvovec) in markets outside of the United States. Luxturna received FDA approval on December 19, 2017 for the treatment of patients with biallelic mutations in the RPE65 gene. A market authorization application was filed with the EMA on July 31, 2017, and, following approval, Novartis will obtain all commercialization rights. According to the press release, Novartis will make an upfront payment, as well as pay milestones and royalties to Spark Therapeutics reflective of the late stage of the opportunity.
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.